<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112918</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000427299</org_study_id>
    <secondary_id>P30CA016042</secondary_id>
    <secondary_id>UCLA-0412086-01</secondary_id>
    <secondary_id>ROCHE-BO17920A</secondary_id>
    <nct_id>NCT00112918</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer</brief_title>
  <official_title>A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma: The AVANT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies,
      such as bevacizumab, can block tumor growth in different ways. Some block the ability of
      tumor cells to grow and spread. Others find tumor cells and help kill them or carry
      tumor-killing substances to them. Bevacizumab (Bv) may also stop the growth of tumor cells by
      blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab
      after surgery may kill any tumor cells that remain after surgery. It is not yet known whether
      giving combination chemotherapy together with bevacizumab is more effective than combination
      chemotherapy alone in treating colon cancer in adjuvant setting.

      PURPOSE: This randomized phase III trial is studying two different combination chemotherapy
      regimens with or without bevacizumab to compare how well they work in treating patients who
      have undergone surgery for high risk stage II or stage III colon cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label Phase III, multicenter, multinational, randomized, 3-arm study
      designed to evaluate the efficacy and safety of bevacizumab in combination with either
      intermittent fluorouracil/leucovorin with oxaliplatin (FOLFOX4) or capecitabine plus
      oxaliplatin (XELOX) versus FOLFOX4 regimen alone, as adjuvant chemotherapy in colon
      carcinoma.

      The treatment phase consisted of two parts of 24 weeks for a total of 48 weeks. The first
      part (weeks 1 to 24) consisted of treatment with either FOLFOX4, FOLFOX4 in combination with
      bevacizumab, or XELOX in combination with bevacizumab. The second part (weeks 25 to 48)
      consisted of single-agent bevacizumab for patients randomized to either
      bevacizumab-containing arm, but was only an observation period for patients assigned to the
      FOLFOX4-alone arm.

      Patients were to be followed for recurrence/new occurrence of colorectal cancer and survival.
      Patients who experienced a confirmed recurrence, occurrence of a new colorectal cancer during
      therapy, or experienced unacceptable toxicity were to be taken off study treatment but remain
      in study follow-up. Patients that came off therapy due to a confirmed recurrence/appearance
      of new colorectal cancer, were to be followed for survival until the end of the study
      follow-up period. The primary analysis was performed 36 months after the last patient has
      been randomized. After the primary analysis, patients continue to be followed for survival
      for at least a further 2 years ie, until all patients have been followed-up for at least 5
      years following randomization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival in Stage III Cancer Patients - Time to Event</measure>
    <time_frame>From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).</time_frame>
    <description>Disease-free survival (DFS) was defined as the time from the date of randomization to the time of a recurrence, a new occurrence of colorectal cancer or death due to any cause, whichever occurred first. Patients without an event were censored at the last date the patient was known to be disease-free. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Patients with no tumor assessments after baseline but still alive at the time of the clinical cut-off were censored at day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free Survival in Stage III Cancer Patients - Number of Events</measure>
    <time_frame>From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).</time_frame>
    <description>A disease-free survival (DFS) event was composed of a recurrence, a new occurrence of colorectal cancer or death due to any cause. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Triggering events for DFS are reported; a patient can have both recurrence and a new occurrence of colon cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in Stage III Cancer Patients - Time to Event</measure>
    <time_frame>From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).</time_frame>
    <description>Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the analysis were censored at the date they were last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in Stage III Cancer Patients - Number of Events</measure>
    <time_frame>From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).</time_frame>
    <description>An overall survival event was death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in Stage III Cancer Patients - Time to Event: Final Analysis</measure>
    <time_frame>From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).</time_frame>
    <description>Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the clinical cut-off date (30 June 2012) were censored at the date they were last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in Stage III Cancer Patients - Number of Events: Final Analysis</measure>
    <time_frame>From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).</time_frame>
    <description>An overall survival event was death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3451</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOX4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Observation only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX4 + Bv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX+Bv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Administered as an intravenous infusion over 30 - 90 minutes.</description>
    <arm_group_label>FOLFOX4 + Bv</arm_group_label>
    <arm_group_label>XELOX+Bv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Film-coated tablets</description>
    <arm_group_label>XELOX+Bv</arm_group_label>
    <other_name>Xeloda®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil (5-FU)</intervention_name>
    <description>Administered as either a bolus injection or continuous intravenous infusion over 22 hours.</description>
    <arm_group_label>FOLFOX4</arm_group_label>
    <arm_group_label>FOLFOX4 + Bv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin calcium</intervention_name>
    <description>Administered as a 200 mg/m^2 infusion over 2 hours.</description>
    <arm_group_label>FOLFOX4</arm_group_label>
    <arm_group_label>FOLFOX4 + Bv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Administered as an intravenous infusion over 2 hours.</description>
    <arm_group_label>FOLFOX4</arm_group_label>
    <arm_group_label>FOLFOX4 + Bv</arm_group_label>
    <arm_group_label>XELOX+Bv</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Signed written informed consent obtained prior to any study specific screening
             procedures.

          2. Patient willing and able to comply with the protocol.

          3. Age ≥ 18 years-of-age.

          4. Histologically confirmed colon carcinoma, American Joint Cancer Committee/Union
             Internationale Contre le Cancer (AJCC/UICC) Stage II or Stage III defined as a tumor
             location ≥ 15 cm from the anal verge by endoscopy or above the peritoneal reflection
             at surgery. The patient was not to be a candidate for (neo) adjuvant radiotherapy.
             Note: Stage II patients were to be considered as high-risk patients fulfilling one of
             the following criteria:

               -  T4 tumours,

               -  Patients presenting with bowel obstruction or perforation,

               -  Histological signs of vascular invasion (i.e. blood and lymphatic vessels) or
                  perineural invasion,

               -  Patients aged less than 50 years,

               -  Patients with sub-optimal surgery (less than 12 nodes analyzed).

          5. Curative surgery not less than 4 and not more than 8 weeks prior to randomization.

          6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          7. Life expectancy of ≥ 5 years.

        Exclusion Criteria

          1. Macroscopic or microscopic evidence of remaining tumour. Patients should never have
             had any evidence of metastatic disease (including presence of tumour cells in the
             ascites). The isolated finding of cytokeratin positive cells in bone marrow is not
             considered evidence of metastatic disease for purposes of this study.

          2. Carcinoembryonic antigen &gt; 1.5 x upper limit of normal (ULN) after surgery (during
             screening period).

          3. For patients with colostomy, unwilling to delay revision until at least 28 days after
             treatment completion.

          4. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study treatment start, not fully healed wounds, or anticipation of the need
             for major surgical procedure during the course of the study. Any central venous access
             device (CVAD) for chemotherapy administration must be inserted at least 2 days prior
             to treatment start.

          5. Previous anti-angiogenic treatment for any malignancy; cytotoxic chemotherapy,
             radiotherapy or immunotherapy for colon cancer.

          6. Other malignancies within the last 5 years (other than curatively treated basal cell
             carcinoma of the skin and/or in situ carcinoma of the cervix).

          7. Females with a positive or no pregnancy test (within 7 days before treatment start)
             unless childbearing potential can be otherwise excluded (postmenopausal i.e.
             amenorrheic for at least 2 years, hysterectomy or oophorectomy).

          8. Lactating women.

          9. Fertile women (&lt; 2 years after last menstruation) and men of childbearing potential
             not willing to use effective means of contraception.

         10. History or evidence upon physical examination of central nervous disease (CNS) disease
             (eg, primary brain tumour, seizure not controlled with standard medical therapy, any
             brain metastases).

         11. History of psychiatric disability judged by the investigator to be clinically
             significant, precluding informed consent or interfering with compliance for oral drug
             intake.

         12. Clinically significant (ie, active) cardiovascular disease. This includes, but is not
             limited to, the following examples: cerebrovascular accidents (≤ 6 months prior to
             randomization), myocardial infarction (≤ 1 year prior to randomization), uncontrolled
             hypertension (&gt;150/100 mmHg) while receiving chronic medication, unstable angina, New
             York Heart Association (NYHA) Grade II or greater congestive heart failure, serious
             cardiac arrhythmia requiring medication, clinically significant electrocardiogram
             (ECG) findings (e.g. QTc ≥ 440 msecs [male] 460 msecs [female] or ≥ 2º
             atrioventricular block, etc.).

             Patients who suffer from serious cardiac arrhythmia requiring medication can enter the
             study only if they are considered to be in a stable condition regarding both the
             arrhythmia and their medication. Patients with pacemakers are allowed to enter the
             study only if they are considered as being in a stable condition. In case of doubt,
             the investigator should obtain a consultation with a local cardiologist.

         13. Lack of physical integrity of the upper gastro-intestinal tract, malabsorption
             syndrome, or inability to take oral medication.

         14. Interstitial pneumonia or extensive symptomatic fibrosis of the lungs.

         15. Known peripheral neuropathy ≥ Common terminology criteria for adverse events (CTCAE)
             version 3.0 Grade 1. Absence of deep tendon reflexes as the sole neurological
             abnormality does not render the patient ineligible.

         16. Organ allografts requiring immunosuppressive therapy.

         17. Serious, non-healing wound, ulcer, or bone fracture.

         18. Evidence of bleeding diathesis or coagulopathy.

         19. Current or recent (within 10 days prior to study treatment start) use of full-dose
             oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes.

         20. Chronic, daily treatment with high-dose aspirin (&gt; 325 mg/day) or clopidogrel (&gt; 75
             mg/day).

         21. Chronic treatment with corticosteroids (dose of ≥ 10 mg/day methylprednisolone
             equivalent) (excluding inhaled steroids).

         22. Serious intercurrent infections (uncontrolled or requiring treatment).

         23. Known dihydropyrimidine dehydrogenase deficiency.

         24. Current or recent (within the 28 days prior to randomization) treatment with another
             investigational drug or participation in another investigational study.

         25. Patients with known allergy to Chinese hamster ovary cell proteins or other
             recombinant human or humanized antibodies or to any excipients of bevacizumab
             formulation, platinum compounds or to any other components of the study drugs.

         26. History or presence of other disease, metabolic dysfunction, physical examination
             finding, or clinical laboratory finding giving reasonable suspicion of a disease or
             condition that contraindicates use of an investigational drug or patient at high risk
             from treatment complications.

         27. Presence of proteinuria at baseline as defined by:

             - Patients with &gt; 1 g of protein/24 hour by a 24-hour urine collection.

         28. Any laboratory values at baseline are as follows:

        Haematology:

          -  Absolute neutrophil count (ANC) &lt; 1.5 x 109/L

          -  Platelet count &lt; 100 x 10^9/L

          -  Haemoglobin &lt; 9 g/dL (may be transfused to maintain or exceed this level)

          -  International normalized ratio (INR) &gt; 1.5

          -  Activated partial prothrombin time (APTT) ≥ 1.5 x ULN

        Biochemistry:

          -  Total bilirubin &gt; 1.5 x ULN

          -  aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT) &gt; 2.5 x ULN

          -  Alkaline phosphatase (ALP) &gt; 2.5 x ULN

          -  Serum creatinine &gt; 1.5 x ULN or creatinine clearance ≤ 50 mL/min (e.g. Cockcroft-Gault
             formula).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Randolph Hecht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <results_first_submitted>June 1, 2012</results_first_submitted>
  <results_first_submitted_qc>August 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 6, 2012</results_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Randomization was stratified according to geographic region and disease stage (high-risk stage II or stage III N1 or stage III N2). The primary analysis population consisted of patients with Stage III disease.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FOLFOX4</title>
          <description>Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-fluorouracil (5-FU), given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Observation only.</description>
        </group>
        <group group_id="P2">
          <title>FOLFOX4 + Bv</title>
          <description>Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
        </group>
        <group group_id="P3">
          <title>XELOX+Bv</title>
          <description>Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1151"/>
                <participants group_id="P2" count="1155"/>
                <participants group_id="P3" count="1145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1126"/>
                <participants group_id="P2" count="1145">Includes two patients from FOLFOX4 who received Bv and were assigned to FOLFOX4+Bv safety analysis</participants>
                <participants group_id="P3" count="1135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Stage III Disease Population</title>
              <participants_list>
                <participants group_id="P1" count="955"/>
                <participants group_id="P2" count="960"/>
                <participants group_id="P3" count="952"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="854">Represents patients alive in follow-up at the time of final data cut-off (30 June 2012)</participants>
                <participants group_id="P2" count="810">Represents patients alive in follow-up at the time of final data cut-off (30 June 2012)</participants>
                <participants group_id="P3" count="846">Represents patients alive in follow-up at the time of final data cut-off (30 June 2012)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="297"/>
                <participants group_id="P2" count="345"/>
                <participants group_id="P3" count="299"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Measures are based on the Intent-to-Treat - Stage III Disease Patient Population.</population>
      <group_list>
        <group group_id="B1">
          <title>FOLFOX4</title>
          <description>Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-fluorouracil (5-FU), given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Observation only.</description>
        </group>
        <group group_id="B2">
          <title>FOLFOX4 + Bv</title>
          <description>Weeks 1–24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 – 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25–48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
        </group>
        <group group_id="B3">
          <title>XELOX+Bv</title>
          <description>Weeks 1–24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 – 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).
Weeks 25–48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="955"/>
            <count group_id="B2" value="960"/>
            <count group_id="B3" value="952"/>
            <count group_id="B4" value="2867"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="603"/>
                    <measurement group_id="B2" value="625"/>
                    <measurement group_id="B3" value="588"/>
                    <measurement group_id="B4" value="1816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="296"/>
                    <measurement group_id="B4" value="832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="425"/>
                    <measurement group_id="B2" value="473"/>
                    <measurement group_id="B3" value="432"/>
                    <measurement group_id="B4" value="1330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="530"/>
                    <measurement group_id="B2" value="487"/>
                    <measurement group_id="B3" value="520"/>
                    <measurement group_id="B4" value="1537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="791"/>
                    <measurement group_id="B2" value="813"/>
                    <measurement group_id="B3" value="795"/>
                    <measurement group_id="B4" value="2399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival in Stage III Cancer Patients - Time to Event</title>
        <description>Disease-free survival (DFS) was defined as the time from the date of randomization to the time of a recurrence, a new occurrence of colorectal cancer or death due to any cause, whichever occurred first. Patients without an event were censored at the last date the patient was known to be disease-free. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Patients with no tumor assessments after baseline but still alive at the time of the clinical cut-off were censored at day 1.</description>
        <time_frame>From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).</time_frame>
        <population>The primary population for efficacy analyses was the intent to treat population (ITT; all randomized patients) with stage III disease.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX4</title>
            <description>Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Observation only.</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX4 + Bv</title>
            <description>Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
          </group>
          <group group_id="O3">
            <title>XELOX+Bv</title>
            <description>Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival in Stage III Cancer Patients - Time to Event</title>
          <description>Disease-free survival (DFS) was defined as the time from the date of randomization to the time of a recurrence, a new occurrence of colorectal cancer or death due to any cause, whichever occurred first. Patients without an event were censored at the last date the patient was known to be disease-free. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Patients with no tumor assessments after baseline but still alive at the time of the clinical cut-off were censored at day 1.</description>
          <population>The primary population for efficacy analyses was the intent to treat population (ITT; all randomized patients) with stage III disease.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="955"/>
                <count group_id="O2" value="960"/>
                <count group_id="O3" value="952"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median time to event and 95% confidence intervals could not be estimated due to the low number of events.</measurement>
                    <measurement group_id="O2" value="NA">Median time to event and 95% confidence intervals could not be estimated due to the low number of events.</measurement>
                    <measurement group_id="O3" value="NA">Median time to event and 95% confidence intervals could not be estimated due to the low number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Adjustments for multiplicity was done using a closed test procedure which tests for differences between all three treatment groups at the 5% alpha level first. Only in case of a significant result, the pair-wise comparison between the control arm and each of the bevacizumab arm will be tested, again at the 5% alpha level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2024</p_value>
            <method>Closed test procedure</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in Stage III Cancer Patients - Time to Event</title>
        <description>Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the analysis were censored at the date they were last known to be alive.</description>
        <time_frame>From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).</time_frame>
        <population>ITT patients with Stage III disease.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX4</title>
            <description>Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Observation only.</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX4 + Bv</title>
            <description>Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
          </group>
          <group group_id="O3">
            <title>XELOX+Bv</title>
            <description>Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in Stage III Cancer Patients - Time to Event</title>
          <description>Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the analysis were censored at the date they were last known to be alive.</description>
          <population>ITT patients with Stage III disease.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="955"/>
                <count group_id="O2" value="960"/>
                <count group_id="O3" value="952"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median time to event and 95% confidence intervals could not be estimated due to the low number of events.</measurement>
                    <measurement group_id="O2" value="NA">Median time to event and 95% confidence intervals could not be estimated due to the low number of events.</measurement>
                    <measurement group_id="O3" value="NA">Median time to event and 95% confidence intervals could not be estimated due to the low number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival in Stage III Cancer Patients - Number of Events</title>
        <description>A disease-free survival (DFS) event was composed of a recurrence, a new occurrence of colorectal cancer or death due to any cause. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Triggering events for DFS are reported; a patient can have both recurrence and a new occurrence of colon cancer.</description>
        <time_frame>From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).</time_frame>
        <population>The primary population for efficacy analyses was the intent to treat population (ITT; all randomized patients) with stage III disease.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX4</title>
            <description>Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Observation only.</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX4 + Bv</title>
            <description>Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
          </group>
          <group group_id="O3">
            <title>XELOX+Bv</title>
            <description>Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival in Stage III Cancer Patients - Number of Events</title>
          <description>A disease-free survival (DFS) event was composed of a recurrence, a new occurrence of colorectal cancer or death due to any cause. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Triggering events for DFS are reported; a patient can have both recurrence and a new occurrence of colon cancer.</description>
          <population>The primary population for efficacy analyses was the intent to treat population (ITT; all randomized patients) with stage III disease.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="955"/>
                <count group_id="O2" value="960"/>
                <count group_id="O3" value="952"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with a DFS event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                    <measurement group_id="O2" value="280"/>
                    <measurement group_id="O3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="253"/>
                    <measurement group_id="O3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Occurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="718"/>
                    <measurement group_id="O2" value="680"/>
                    <measurement group_id="O3" value="699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in Stage III Cancer Patients - Number of Events</title>
        <description>An overall survival event was death due to any cause.</description>
        <time_frame>From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).</time_frame>
        <population>ITT patients with Stage III disease.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX4</title>
            <description>Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Observation only.</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX4 + Bv</title>
            <description>Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
          </group>
          <group group_id="O3">
            <title>XELOX+Bv</title>
            <description>Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in Stage III Cancer Patients - Number of Events</title>
          <description>An overall survival event was death due to any cause.</description>
          <population>ITT patients with Stage III disease.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="955"/>
                <count group_id="O2" value="960"/>
                <count group_id="O3" value="952"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="840"/>
                    <measurement group_id="O2" value="809"/>
                    <measurement group_id="O3" value="807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in Stage III Cancer Patients - Time to Event: Final Analysis</title>
        <description>Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the clinical cut-off date (30 June 2012) were censored at the date they were last known to be alive.</description>
        <time_frame>From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).</time_frame>
        <population>ITT patients with Stage III disease.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX4</title>
            <description>Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Observation only.</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX4 + Bv</title>
            <description>Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
          </group>
          <group group_id="O3">
            <title>XELOX+Bv</title>
            <description>Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in Stage III Cancer Patients - Time to Event: Final Analysis</title>
          <description>Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the clinical cut-off date (30 June 2012) were censored at the date they were last known to be alive.</description>
          <population>ITT patients with Stage III disease.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="955"/>
                <count group_id="O2" value="960"/>
                <count group_id="O3" value="952"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median time to event and 95% confidence intervals could not be estimated due to the low number of events.</measurement>
                    <measurement group_id="O2" value="NA">Median time to event and 95% confidence intervals could not be estimated due to the low number of events.</measurement>
                    <measurement group_id="O3" value="NA">Median time to event and 95% confidence intervals could not be estimated due to the low number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in Stage III Cancer Patients - Number of Events: Final Analysis</title>
        <description>An overall survival event was death due to any cause.</description>
        <time_frame>From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).</time_frame>
        <population>ITT patients with Stage III disease.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX4</title>
            <description>Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Observation only.</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX4 + Bv</title>
            <description>Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
          </group>
          <group group_id="O3">
            <title>XELOX+Bv</title>
            <description>Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).
Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in Stage III Cancer Patients - Number of Events: Final Analysis</title>
          <description>An overall survival event was death due to any cause.</description>
          <population>ITT patients with Stage III disease.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="955"/>
                <count group_id="O2" value="960"/>
                <count group_id="O3" value="952"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="202"/>
                    <measurement group_id="O3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="794"/>
                    <measurement group_id="O2" value="758"/>
                    <measurement group_id="O3" value="770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events occurring between the date of first drug intake and 28 days after last drug intake, regardless of which treatment group the patient was randomized to.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FOLFOX4</title>
          <description>Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with Leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25-48: Observation only.</description>
        </group>
        <group group_id="E2">
          <title>FOLFOX4 + Bv</title>
          <description>Weeks 1–24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 – 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
Weeks 25–48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
        </group>
        <group group_id="E3">
          <title>XELOX+Bv</title>
          <description>Weeks 1–24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 – 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).
Weeks 25–48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="226" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="297" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="284" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenia purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Paroxysmal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abdominal rigidity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Gastric volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hiatus hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Ileal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Intestinal angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Intestinal dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Intestinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Intestinal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Intestinal strangulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Rectal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Volvulus of small bowel</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Adhesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Infusion site thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Visceral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cytolytic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Anaphylactiod reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Enteritis infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Herpes zoster ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Incision site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Intestinal fistual infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Overgrowth bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Puncture site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Accident at work</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Anastomotic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Brachial plexus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Leukoaraiosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Orthostatic intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurological deficit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Reversible posterior leukoencephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Nephrogenic diabetes insipidus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Dysaesthesia pharynx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Palmar-Plantar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Pregnancy of partner</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Central venous catheter removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Axillary vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1112" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="1127" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="1117" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="660" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="567" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="273" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="331" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="725" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="761" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="720" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="620" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="699" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="699" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="385" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="394" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="460" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="310" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="360" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="246" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="308" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="324" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="219" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="220" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="227" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="214" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="404" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="425" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="355" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="241" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="251" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="250" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="106" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="268" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="324" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="295" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="122" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="430" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="430" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="436" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="310" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="328" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="314" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="252" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="234" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="204" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="284" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="219" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="237" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="222" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="152" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="128" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="424" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="216" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Dysaesthesia pharynx</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-Plantar Erythrodysaesthesia Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="435" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="231" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="241" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="1135"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="1126"/>
                <counts group_id="E2" subjects_affected="472" subjects_at_risk="1145"/>
                <counts group_id="E3" subjects_affected="468" subjects_at_risk="1135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffman-LaRoche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

